01—Abstract
Summary
Summary of the 8-K filed February 19, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter 2024 revenue of $1.00 billiona, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023, with organic revenue down 1.8%.
The company recorded a non-cash goodwill impairment of $215.0 millionb in the quarter related to its Biologics Solutions reporting unit, producing a GAAP net loss available to common shareholders of $(215.7) million, or $(4.22) per share. On a non-GAAP basis, fourth-quarter diluted earnings per share rose 8.1% to $2.66 from $2.46, driven by higher operating income and favorable below-the-line items. For full-year 2024, revenue decreased 1.9% to $4.05 billion from $4.13 billion, with organic revenue down 2.8%.
GAAP diluted EPS was $0.20c, down from $9.22 in 2023, while non-GAAP diluted EPS was $10.32, down 3.3% from $10.67. Segment results were mixed: Research Models and Services and Manufacturing Solutions grew full-year revenue, while Discovery and Safety Assessment revenue declined 6.3%.
For 2025, management guides reported revenue growth of (7.0)% to (4.5)% and GAAP EPS of $4.30 to $4.80d, with non-GAAP EPS of $9.10 to $9.60. The company expects DSA pricing to be a headwind throughout 2025, lower commercial CDMO revenue to weigh on Manufacturing growth, and plans to repurchase approximately $350 million of common stock in 2025.
02—Key points
Key Highlights
- Q4 2024 revenue of $1.00 billion, down 1.1% reported and 1.8% organic; Manufacturing Solutions organic growth of 2.1% was offset by declines in DSA and RMS.
- A $215.0 million non-cash goodwill impairment tied to Biologics Solutions drove a Q4 GAAP loss per share of $(4.22); the impairment equaled $4.20 per share in the quarter.
- Q4 non-GAAP diluted EPS rose 8.1% to $2.66, with non-GAAP operating margin improving to 19.9% from 19.1%.
- Full-year 2024 GAAP diluted EPS was $0.20 versus $9.22 in 2023; non-GAAP diluted EPS was $10.32, down 3.3%.
- 2025 guidance calls for reported revenue decline of (7.0)% to (4.5)% and non-GAAP EPS of $9.10 to $9.60.
- Management expects DSA pricing to be a headwind throughout 2025 and lower commercial CDMO revenue to slow Manufacturing growth.
- The company plans to repurchase approximately $350 million of common stock in 2025.
03—Questions
Frequently Asked Questions
Why did CRL report a large GAAP loss in the fourth quarter of 2024?
The loss was driven primarily by a non-cash goodwill impairment of $215.0 million related to the Biologics Solutions reporting unit, which includes the Biologics Testing and CDMO businesses. The impairment followed a loss of key customers and a reduction in that unit's long-range outlook. The company also recorded a $0.32 per share loss on venture capital and strategic investments in the quarter.
How did the segments perform in 2024?
Research Models and Services revenue rose 4.7% to $829.4 million, though organic revenue declined 0.1%. Discovery and Safety Assessment revenue fell 6.3% to $2.45 billion, with organic revenue down 6.2%. Manufacturing Solutions revenue grew 6.6% to $769.3 million, with organic growth of 6.8%, though its GAAP operating margin was negative due to the goodwill impairment.
What does the 2025 guidance imply for earnings?
Management expects GAAP EPS of $4.30 to $4.80 and non-GAAP EPS of $9.10 to $9.60. The company says earnings will be principally affected by lower revenue, partially offset by benefits from restructuring cost savings. Guidance includes approximately $3.50 per share of acquisition-related amortization and integration costs, and about $1.00 per share of restructuring costs.
What is the company's capital return plan for 2025?
Charles River plans to repurchase approximately $350 million of its common stock in 2025. In 2024, it had already spent $119.2 million on purchases of treasury stock, according to the cash flow statement.
04—Continue